Literature DB >> 9610589

Ability of sextant biopsies to predict radical prostatectomy stage.

M L Wills1, J Sauvageot, A W Partin, R Gurganus, J I Epstein.   

Abstract

OBJECTIVES: There are few studies evaluating multiple variables on sextant biopsies with the intent to predict stage in radical prostatectomy specimens.
METHODS: We studied 113 sextant biopsies with corresponding totally submitted radical prostatectomy specimens. Variables evaluated on sextant biopsies included total length and percent of cancer; maximum length and percent of cancer on one core; location (apex, mid, base); bilaterality; Gleason grade; number of cores involved; serum prostate-specific antigen (PSA) level; and serum PSA density (PSAD). Radical prostatectomy stage was classified as organ versus non-organ confined.
RESULTS: The following variables individually correlated with radical prostatectomy stage: total cancer measured in millimeters (P <0.0001) or percent (P <0.0005); biopsy Gleason score (P <0.0001); number of involved cores (P <0.0001); maximum cancer on one core measured in millimeters (P = 0.0001); maximum percent of cancer on one core (P = 0.01); bilaterality (P = 0.01); PSA level (P = 0.03), and PSAD (P = 0.001). The most predictive sets of two variables that correlated with stage included high Gleason score (P <0.0001) combined with numbers of cores involved (P = 0.002). When biopsies had Gleason scores of 6 or less, two or fewer positive cores, and serum PSA of 0 to 4 ng/mL, 89% were organ confined. When biopsies had Gleason scores of 6 or less with two unilaterally positive cores, 87% were organ confined. In biopsies with Gleason scores of 7 or more and more than one positive core, only 10% were organ confined.
CONCLUSIONS: The most important predictors of stage by sextant needle biopsy evaluation are numbers of cores involved with carcinoma and high Gleason score. Bilaterality and serum PSA values improved prediction in two small subgroups. In 37% of our population we were able to predict with a greater than 87% probability the organ-confined versus non-organ-confined status.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9610589     DOI: 10.1016/s0090-4295(98)00011-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  14 in total

1.  Various morphometric measurements of cancer extent on needle prostatic biopsies: which is predictive of pathologic stage and biochemical recurrence following radical prostatectomy?

Authors:  Maisa M Q Quintal; Luciana R Meirelles; Leandro L L Freitas; Luis A Magna; Ubirajara Ferreira; Athanase Billis
Journal:  Int Urol Nephrol       Date:  2011-02-22       Impact factor: 2.370

2.  Significance of the percentage of prostate needle biopsy cores with cancer as a predictor of disease extension in radical prostatectomy specimens in Japanese men.

Authors:  Iori Sakai; Ken-ichi Harada; Isao Hara; Hiroshi Eto; Hideaki Miyake
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  Pre-operative prediction of advanced prostatic cancer using clinical decision support systems: accuracy comparison between support vector machine and artificial neural network.

Authors:  Sang Youn Kim; Sung Kyoung Moon; Dae Chul Jung; Sung Il Hwang; Chang Kyu Sung; Jeong Yeon Cho; Seung Hyup Kim; Jiwon Lee; Hak Jong Lee
Journal:  Korean J Radiol       Date:  2011-08-24       Impact factor: 3.500

4.  Prostate cancer: epidemiology and screening.

Authors:  Timothy J Wilt
Journal:  Rev Urol       Date:  2003

5.  Prostate cancer: epidemiology and screening.

Authors:  M K Brawer; E D Crawford; J Fowler; M S Lucia; F H Schröeder
Journal:  Rev Urol       Date:  2000

6.  Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment.

Authors:  K R Keshari; H Tsachres; R Iman; L Delos Santos; Z L Tabatabai; K Shinohara; D B Vigneron; J Kurhanewicz
Journal:  NMR Biomed       Date:  2011-07       Impact factor: 4.044

7.  Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort.

Authors:  Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Tim Oliver; Henrik Møller; Victor Reuter; Peter Scardino; Jack Cuzick; Daniel M Berney
Journal:  Virchows Arch       Date:  2010-09-09       Impact factor: 4.064

Review 8.  Advances in MR spectroscopy of the prostate.

Authors:  John Kurhanewicz; Daniel B Vigneron
Journal:  Magn Reson Imaging Clin N Am       Date:  2008-11       Impact factor: 2.266

9.  Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists.

Authors:  D M Berney; F Algaba; P Camparo; E Compérat; D Griffiths; G Kristiansen; A Lopez-Beltran; R Montironi; M Varma; L Egevad
Journal:  Virchows Arch       Date:  2014-03-04       Impact factor: 4.064

Review 10.  The role of metabolic imaging in radiation therapy of prostate cancer.

Authors:  V Y Zhang; A Westphalen; L Delos Santos; Z L Tabatabai; K Shinohara; D B Vigneron; J Kurhanewicz
Journal:  NMR Biomed       Date:  2013-08-12       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.